Humulin N (Insulin Human)

Humulin N is indicated for the long‑acting basal insulin needs of adults and children with diabetes. It is commonly prescribed as part of a comprehensive diabetes management plan.

• Basal insulin therapy for type 1 diabetes mellitus.
• Basal insulin therapy for type 2 diabetes mellitus.
• Adjunct to rapid‑acting insulin for mixed‑meal regimens.
• Use in patients requiring a steady, prolonged insulin effect.
• May be combined with oral antidiabetic agents when appropriate.

• Humulin N provides a prolonged supply of insulin human that binds to insulin receptors on muscle, adipose, and hepatic cells. This binding activates the receptor’s intrinsic tyrosine kinase activity, promoting translocation of glucose transporter proteins to the cell surface, increasing glucose uptake, and enhancing glycogen synthesis. In the liver, it suppresses gluconeogenesis, thereby reducing endogenous glucose production and contributing to overall glycemic control.

Humulin N may cause a range of adverse reactions, varying from mild to severe.

Common

• Hypoglycemia (low blood glucose).
• Injection site redness, swelling, or itching.
• Lipodystrophy at the injection site.
• Weight gain.
• Mild headache.

Serious

• Severe hypoglycemia with loss of consciousness.
• Allergic reactions such as rash, urticaria, or anaphylaxis.
• Edema or fluid retention.
• Persistent hypoglycemia requiring medical intervention.

When using Humulin N, several safety considerations should be observed.

• Monitor blood glucose regularly to avoid hypoglycemia.
• Adjust dose during periods of illness, stress, or changes in diet.
• Use caution in patients with renal or hepatic impairment.
• Pregnancy and lactation status should be evaluated; safety data are limited.
• Educate patients on proper injection technique to reduce lipodystrophy.
• Store the product according to manufacturer instructions to maintain potency.

Humulin N can interact with other medications, affecting its efficacy or safety.

Avoid

• Concurrent use of other insulin products without dose adjustment.
• Beta‑blockers that may mask hypoglycemia symptoms.
• High‑dose corticosteroids that increase glucose levels.

Use with caution

• Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that may potentiate hypoglycemia.
• MAO‑inhibitors and certain antidepressants that can alter glucose metabolism.
• Alcohol consumption, which can unpredictably affect blood glucose.